In response to President Donald Trump’s implementation of historic tariffs, various sectors and leaders are expressing concerns and reactions. Eli Lilly CEO David Ricks has cautioned that the broad tariffs could have negative implications for drug research and development within the pharmaceutical industry. Despite this, Trump’s reciprocal tariffs have exempted certain trading partners from the measures.
Top trade advisor Peter Navarro has sought to downplay the market sell-off following the tariff announcements. Meanwhile, Elon Musk has criticized Navarro’s qualifications in handling trade matters. Musk’s comments add to the ongoing debate and scrutiny surrounding the Trump administration’s trade policies.
Silicon valley business review 